{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:39Z","timestamp":1792603059664,"version":"4.5.0"},"reference-count":36,"publisher":"Wiley","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2002,1,2]],"date-time":"2002-01-02T00:00:00Z","timestamp":1009929600000},"content-version":"vor","delay-in-days":397,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1034\/j.1600-0404.2000.00310.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T21:26:12Z","timestamp":1047331572000},"page":"68-73","source":"Crossref","is-referenced-by-count":123,"special_numbering":"supplement s176","title":["Galantamine is an allosterically potentiating ligand of the human \u03b14\/\u03b22\u2003nAChR"],"prefix":"10.1155","volume":"102","author":[{"given":"M.","family":"Samochocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jostock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Groot Kormelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. M. L.","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. X.","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maelicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,2]]},"reference":[{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB1|cit2","first-page":"pp.\u2003181","volume-title":"Cholinesterases and cholinesterase inhibitors","author":"Giacobini","year":"2000"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB2|cit3","first-page":"708","article-title":"Enhancement of memory by physostigmine in Alzheimer's disease","volume":"102","author":"Davis","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB3|cit4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/0024-3205(78)90100-5","article-title":"Cholinergic underactivity in human memory disorders","volume":"23","author":"Davis","year":"1978","journal-title":"Life Sci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB4|cit5","doi-asserted-by":"publisher","first-page":"13541","DOI":"10.1073\/pnas.93.24.13541","article-title":"Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease","volume":"93","author":"Levey","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB5|cit6","first-page":"55","article-title":"Nicotinic acetylcholine binding sites in Alzheimer's disease","volume":"1","author":"Whitehouse","year":"1986","journal-title":"Brain Res"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB6|cit7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0304-3940(86)90629-4","article-title":"Reduced number of (3H) nicotine and (3H) acetylcholine binding sites in the frontal cortex of Alzheimer brains","volume":"72","author":"Nordberg","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB7|cit8","first-page":"259","article-title":"Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol","volume":"12","author":"Schr\u00f6der","year":"1991","journal-title":"Aging"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB8|cit9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0306-4522(94)00410-7","article-title":"Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology","volume":"64","author":"Perry","year":"1995","journal-title":"Neuroscience"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB9|cit10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002093-199505000-00006","article-title":"Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: in vivo assessment using positron emission tomography","volume":"9","author":"Nordberg","year":"1995","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB10|cit11","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1046\/j.1460-9568.1999.00676.x","article-title":"Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - Histotopographical correlation with amyloid plaques and hyperphosphorylated tau-protein","volume":"11","author":"Wevers","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB11|cit12","doi-asserted-by":"crossref","unstructured":"Martin-Ruiz CM Court JA Molnar E et\u00a0al \u03b14 but not \u03b13 and \u03b17 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease J Neurochem 1999:73 1635 40","DOI":"10.1046\/j.1471-4159.1999.0731635.x"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB12|cit13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1523\/JNEUROSCI.20-01-00066.2000","article-title":"Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks","volume":"20","author":"Alkondon","year":"2000","journal-title":"J Neurosci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB13|cit14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0014-5793(96)01115-5","article-title":"Stable expression in HEK-293 cells of the rat \u03b13\/\u03b24 subtype of neuronal nicotinic acetylcholine receptor","volume":"397","author":"Stetzer","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB14|cit15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0014-5793(96)01383-x","article-title":"Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic receptor (nAChR) subunits \u03b23 and \u03b24 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and\/or IMR-32","volume":"400","author":"Groot Kormelink","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB15|cit16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1432-1033.1991.tb16231.x","article-title":"A second pathway of activation of the Torpedo acetylcholine receptor channel","volume":"200","author":"Okonjo","year":"1991","journal-title":"Eur J Biochem"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB16|cit17","first-page":"768","article-title":"Physostigmine and galantamine: probes for a novel binding site on the \u03b14\u03b22 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells","volume":"270","author":"Pereira","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB17|cit18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/smns.1995.0012","article-title":"Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system","volume":"7","author":"Maelicke","year":"1995","journal-title":"Seminars Neurosci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB18|cit19","first-page":"1","article-title":"Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands","volume":"49","author":"Schrattenholz","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB19|cit20","first-page":"1474","article-title":"Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons","volume":"265","author":"Pereira","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB20|cit21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1432-1033.1993.tb18187.x","article-title":"Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine","volume":"216","author":"Schrattenholz","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB21|cit22","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1016\/S0021-9258(17)34075-9","article-title":"Mono-clonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor \u03b1-polypeptide","volume":"269","author":"Schr\u00f6der","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB22|cit23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/1359-6446(96)89089-1","article-title":"New approach to drug therapy of Alzheimer's dementia","volume":"1","author":"Maelicke","year":"1996","journal-title":"Drug Disc Today"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB23|cit24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0014-2999(00)00093-5","article-title":"Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease","volume":"393","author":"Maelicke","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB24|cit25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/anie.198401951","article-title":"Biochemical aspects of cholinergic excitation","volume":"23","author":"Maelicke","year":"1984","journal-title":"Angew Chem Int Ed"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB25|cit26","doi-asserted-by":"crossref","unstructured":"Bertrand D Changeux JP Nicotinic receptor: an allosteric protein specialized for intercellular communication Seminars Neurosci 7 75 90","DOI":"10.1006\/smns.1995.0010"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB26|cit27","doi-asserted-by":"crossref","unstructured":"Maelicke A Schrattenholz A Samochocki M Radina M Albuquerque A Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease Behav Brain Res 2000","DOI":"10.1016\/S0166-4328(00)00214-X"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB27|cit28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0922-4106(95)00080-1","article-title":"Physo-stigmine, galantamine and codeine act as non-competitive nicotinic agonists on clonal rat pheochromocytoma cells","volume":"290","author":"Storch","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB28|cit29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology","volume":"19","author":"Nordberg","year":"1998","journal-title":"Drug Safety"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB29|cit30","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1212\/WNL.52.6.1146","article-title":"A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease","volume":"52","author":"Thal","year":"1999","journal-title":"Neurology"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB30|cit31","volume-title":"Clinical expert report","author":"Parys","year":"1999"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB31|cit32","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1111\/j.1460-9568.1997.tb01702.x","article-title":"Choline is a selective agonist of \u03b17 nicotinic acetylcholine receptors","volume":"9","author":"Alkondon","year":"1997","journal-title":"Eur J Neurosci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB32|cit33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s002130050667","article-title":"Nicotinic acetylcholine involvement in cognitive function in animals","volume":"138","author":"Levin","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB33|cit34","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1523\/JNEUROSCI.19-07-02693.1999","article-title":"Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices","volume":"19","author":"Alkondon","year":"1999","journal-title":"J Neurosci"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB34|cit35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1124\/mol.51.5.776","article-title":"Chronic nicotine treatment upregulates \u03b13 AChRs and \u03b17 AChRs expressed by the human neuroblastoma cell line SH-SY5Y","volume":"51","author":"Peng","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB35|cit36","first-page":"216","article-title":"CNS nicotine receptors","volume":"2","author":"Court","year":"1994","journal-title":"Possible therapeutic targets in neurodegenerative disorders. CNS Drugs"},{"key":"10.1034\/j.1600-0404.2000.00310.x-BIB36|cit37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/s0006-8993(98)00138-3","article-title":"Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity","volume":"792","author":"Kihara","year":"1998","journal-title":"Brain Res"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0404.2000.00310.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0404.2000.00310.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1034\/j.1600-0404.2000.00310.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:43:09Z","timestamp":1671522189000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1034\/j.1600-0404.2000.00310.x"}},"subtitle":["Galantamine is a nicotinic APL"],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1034\/j.1600-0404.2000.00310.x","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}